Amide CEST at 7T: A possible biomarker for response to neoadjuvant chemotherapy in breast cancer
Erwin Krikken1, Moritz Zaiss2, Vitaliy Khlebnikov1, Hanneke W.M. van Laarhoven3, Dennis W.J. Klomp1, and Jannie P. Wijnen1
1Radiology, University Medical Center Utrecht, Utrecht, Netherlands, 2Deutsches Krebforschungszentrum, Heidelberg, Germany, 3Medical Oncology, Academic Medical Center Amsterdam, Amsterdam, Netherlands
Neoadjuvant chemotherapy has an important role
in the treatment of breast cancer and the need for early detection of treatment
response is high. As a non-invasive method able to predict treatment response
is lacking, we investigated the feasibility of using amide CEST MRI at 7T as a
biomarker. Six patients were included after informed consent was given. The ATP
signal was robust and repeatedly detectable in the same patient. Significant
differences were seen in amide signal before and after the first cycle of chemotherapy.
This abstract and the presentation materials are available to members only;
a login is required.
